Key Takeaways
Hormone pellet insertion is a subcutaneous procedure performed in-office under local anesthesia
Pellets typically last 3-6 months and release bioidentical testosterone or estradiol
Proper sterile technique and post-procedure documentation are critical for compliance
CPT coding for pellet insertion depends on pellet type and quantity inserted
Patients seeking bioidentical hormone replacement therapy (BHRT) want steady hormone levels without daily dosing, and pellet insertion has become the option that delivers it. The procedure itself is short; the operational tail behind it – baseline labs, consent capture, lot tracking, modifier-correct billing – is where most clinics lose time and revenue.
The average age of menopause in the United States is 52, according to the HHS Office on Women’s Health, and BHRT demand from both perimenopausal women and andropause-affected men has made subcutaneous pellet therapy a recurring revenue line at endocrinology, gynecology, and integrative-medicine practices.
What is Hormone Pellet Insertion?
Hormone pellet insertion is a minor surgical procedure that places compounded bioidentical hormones beneath the skin. The pellets are typically inserted into the fatty tissue of the upper buttock or hip area. Each pellet is cylindrical, approximately 3.2mm (1/8 inch) in diameter and 9mm in length, and dissolves slowly over 3-6 months.
Two hormone types are commonly used. Testosterone pellets address andropause symptoms in men and certain hormonal imbalances in women. Estradiol pellets are used primarily in women for menopausal symptom management. Both are classified as bioidentical hormones, meaning their molecular structure matches hormones produced naturally by the body.
The FDA has approved testosterone pellets (brand name Testopel) for subcutaneous implantation. Compounded versions are also widely used under state pharmacy regulations. Estradiol pellets are typically compounded, as no FDA-approved pellet formulation currently exists for estrogen replacement via subcutaneous implantation.
Pellet therapy differs from other hormone delivery methods in its pharmacokinetics. Unlike transdermal creams or oral tablets, pellets provide continuous hormone release without daily dosing. This consistency eliminates the peaks and troughs seen with injections or topical applications. For clinics, this translates to fewer follow-up visits for dose adjustments and higher patient compliance rates.
From a practice workflow perspective, hormone pellet insertion requires dedicated supplies (trocar sets, local anesthetics, sterile drapes), clear consent protocols, and structured post-procedure monitoring. Clinics using HRT clinic software can automate appointment reminders, consent capture, and follow-up scheduling to streamline the full treatment cycle.
Hormone Pellet Insertion: Pre-Procedure Patient Preparation
Patient preparation begins with lab work. Baseline hormone levels (total testosterone, free testosterone, estradiol, SHBG, and thyroid markers) must be documented before the first testosterone pellet insertion or estrogen pellet insertion. These labs establish the treatment rationale and serve as the reference point for post-insertion monitoring.
Contraindications must be screened during the consultation. Absolute contraindications for testosterone pellet insertion include active prostate cancer, untreated sleep apnea, and polycythemia. For estrogen pellet insertion, contraindications include a history of estrogen-sensitive cancers, active thromboembolic disease, and undiagnosed vaginal bleeding. Document these screenings in the patient record to demonstrate medical necessity and informed consent.

Informed consent must cover five core areas: expected benefits, potential side effects, alternative delivery methods, pellet dissolution timeline, and the need for follow-up labs. Many clinics use digital forms to capture consent electronically before the appointment, reducing paperwork during the procedure day.
Patient instructions for the day of the procedure are straightforward. Avoid blood-thinning medications (aspirin, NSAIDs) for 3-5 days before insertion to minimise bruising risk. Wear loose-fitting clothing to avoid pressure on the insertion site. Arrive with a clean insertion area-patients should shower the morning of the appointment.
Pre-Procedure Checklist for Hormone Pellet Placement
- Baseline lab results reviewed and documented
- Contraindications screened and documented
- Informed consent signed (digital or paper)
- Patient medication list reviewed for anticoagulants
- Insertion site selected and marked (upper buttock/hip)
- Sterile supplies prepared (trocar, lidocaine, steri-strips)
Clinics that perform 20+ hormone pellet insertions per month benefit from templated workflows. Pre-appointment checklists, standardised lab panels, and automated consent reminders reduce the administrative burden on front-desk staff and ensure no steps are missed before the patient arrives.
Step-by-Step Hormone Pellet Insertion Technique
The hormone pellet insertion procedure takes 10-15 minutes when performed by an experienced provider. The patient lies face-down on the exam table with the insertion site exposed. The upper buttock or hip area (approximately 5cm lateral to the iliac crest) is the standard anatomical location due to its subcutaneous fat layer and low risk of vascular injury.
Step 1: Site Preparation and Anesthesia
Clean the insertion site with chlorhexidine or povidone-iodine. Allow the antiseptic to dry completely-premature injection into wet antiseptic reduces local anesthetic efficacy. Mark the insertion point with a sterile surgical marker. Inject 1-2ml of 1% lidocaine with epinephrine into the subcutaneous tissue. The epinephrine provides local vasoconstriction, which minimises bleeding during trocar insertion.
Wait 3-5 minutes for the anesthetic to take full effect. Test the site by gently pressing with a sterile instrument-the patient should report numbness, not pressure pain. This wait time is critical for patient comfort and procedural precision.
Step 2: Trocar Insertion
Make a 3-4mm incision through the epidermis using a #11 scalpel blade. The incision should be just large enough to accommodate the trocar diameter. Insert the trocar at a 30-45 degree angle, advancing it 1-2cm beneath the skin into the subcutaneous fat layer. The trocar creates a channel for pellet placement without damaging surrounding tissue.
Avoid advancing the trocar too deeply-penetrating muscle tissue increases post-procedure discomfort and extrusion risk. The correct depth is subcutaneous fat only. If resistance is felt, withdraw slightly and redirect at a shallower angle.
Step 3: Pellet Placement
Load the pellets into the trocar using the manufacturer’s obturator. Most providers insert 2-10 pellets per session depending on dosing requirements. For testosterone pellet insertion in men, typical dosing ranges from 800-1200mg total (8-12 pellets). For estrogen pellet insertion in women, dosing typically ranges from 50-100mg (5-10 pellets).
Advance the obturator to deposit the pellets at the channel’s distal end. Withdraw the trocar slowly while applying gentle pressure to the skin to prevent pellet extrusion. The entire pellet stack should remain beneath the skin surface.
Step 4: Site Closure and Dressing
Apply manual pressure to the incision site for 30-60 seconds to achieve hemostasis. Close the incision with steri-strips (not sutures-the incision is too small to require stitching). Apply a sterile pressure dressing and secure with medical tape. Instruct the patient to keep the dressing dry and intact for 48 hours.

Document the procedure immediately after completion. Record pellet type, dosage, batch number, insertion site location, and any procedural complications. This documentation supports both medical record completeness and billing accuracy. Practices using AI-powered clinical documentation can dictate procedural notes directly during or immediately after the insertion, reducing charting time.
Streamline Your Hormone Therapy Workflows
Pabau's HRT clinic software automates consent capture, lab result tracking, and post-procedure follow-ups. See how integrated practice management reduces administrative time and improves patient compliance.
Post-Procedure Care and Monitoring
Post-procedure instructions are critical for minimising complications. Patients should avoid strenuous physical activity for 48-72 hours to prevent pellet displacement or extrusion. No swimming, hot tubs, or baths for 5-7 days-moisture increases infection risk. Light walking is acceptable, but avoid activities that generate direct pressure on the insertion site (cycling, prolonged sitting on hard surfaces).
Bruising and minor swelling are normal and resolve within 7-10 days. Instruct patients to apply ice packs (not heat) if swelling occurs. Redness that extends beyond 2cm from the incision site, increasing pain after 48 hours, or purulent drainage indicates potential infection and requires immediate evaluation.
Follow-up labs should be scheduled 4-6 weeks after hormone pellet insertion. This timing captures peak hormone levels and allows dose adjustments before the next insertion cycle. Typical monitoring labs include total testosterone, free testosterone, estradiol, hematocrit, and PSA (for men). Document these results and compare them to baseline values to assess treatment response.
Common Post-Insertion Concerns
Pellet extrusion occurs in less than 2% of cases but requires prompt management. If a pellet extrudes within the first week, the patient should return for evaluation. Extruded pellets cannot be reinserted-document the event and adjust dosing for the next cycle. Chronic extrusion (occurring in multiple cycles) may indicate improper insertion depth or inadequate subcutaneous fat at the chosen site.
Infection rates are extremely low (under 1%) when proper sterile technique is maintained. Signs of infection include fever, warmth at the insertion site, purulent discharge, or spreading erythema. Treat with oral antibiotics (cephalexin or amoxicillin-clavulanate) and consider pellet removal if abscess formation occurs.
Patients sometimes report a palpable lump at the insertion site during the first month. This is normal and represents the pellet stack beneath the skin. The lump diminishes as the pellets dissolve. Reassure patients that this is expected and does not indicate a problem.
Pro Tip
Track pellet lot numbers in every patient record. If a compounding pharmacy issues a recall or quality alert, you can identify affected patients immediately and notify them. This level of traceability is a regulatory expectation and a patient safety standard.
CPT Coding and Billing for Hormone Pellet Insertion
CPT coding for hormone pellet insertion depends on the number of pellets inserted. The primary code is CPT 11980 (Subcutaneous hormone pellet implantation, each). This code is billed per pellet, not per session. If 10 testosterone pellets are inserted, bill CPT 11980 × 10 units.
Modifier usage is critical for multi-pellet sessions. Some payers require modifier -59 (Distinct Procedural Service) when billing multiple units of 11980 in a single session to indicate that each pellet represents a distinct service. Verify payer-specific requirements before submitting claims-incorrect modifier usage is a common denial trigger.
Diagnosis coding must support medical necessity. For testosterone pellet insertion in men, typical ICD-10 codes include E29.1 (Testicular hypofunction) or Z79.890 (Hormone replacement therapy, long-term use). For estrogen pellet insertion in women, use N95.1 (Menopausal and perimenopausal disorders) or Z78.0 (Asymptomatic menopausal state). Link these codes directly to the patient’s documented symptoms and lab findings.
The pellet product itself is billed separately. Use HCPCS code J3490 (Unclassified drugs) for compounded pellets, or J1073 (Testosterone pellet, implant, 75 mg) when billing the FDA-approved Testopel product. J1073 became effective January 1, 2026 and replaced the previously used S0189. Include the NDC number, quantity, and cost on the claim to ensure proper reimbursement.
Pre-procedure consultations are billable separately. Use an appropriate E/M code (99213 or 99214) based on the complexity of the visit. Document the discussion of risks, benefits, alternatives, and the patient’s decision to proceed with hormone pellet therapy. This consultation must occur before the procedure-same-day consultation and insertion requires modifier -25 on the E/M code.
Practices performing 30+ hormone pellet insertions per month should integrate billing workflows with their claims management software. Automated charge capture, code validation, and claim scrubbing reduce manual errors and accelerate reimbursement timelines.
Regulatory Compliance and Documentation Requirements
State medical boards regulate who can perform hormone pellet insertion. In most states, physicians, nurse practitioners, and physician assistants can insert pellets under their scope of practice. Some states require direct physician supervision for NPs and PAs performing this procedure-verify your state’s requirements before delegating pellet insertion to mid-level providers.
Compounded hormone pellets fall under state pharmacy board oversight. The compounding pharmacy must be licensed in the state where the patient resides and must comply with USP 795 and 797 standards for sterile compounding. Request certificates of analysis for each pellet lot to verify potency and sterility. Store these certificates in the clinic’s compliance files.
Informed consent documentation must be retained for the duration of the patient relationship plus the applicable statute of limitations in your state (typically 7-10 years). Digital consent forms stored in secure, HIPAA-compliant systems meet this requirement. Paper consent forms must be scanned and archived with the same retention timeline.
Adverse event reporting is mandatory if a serious complication occurs. Report device-related issues (trocar malfunction, pellet contamination) to the FDA via MedWatch. Report drug-related issues (unexpected hormone toxicity, allergic reaction) to both the FDA and the compounding pharmacy. Document all adverse events in the patient’s medical record and in the clinic’s quality assurance log.
DEA regulations apply if the clinic stocks controlled substances (though hormone pellets themselves are not scheduled drugs). Testosterone is a Schedule III controlled substance in its raw form, but compounded testosterone pellets are typically dispensed directly to the patient by the pharmacy, not stocked at the clinic. Clarify your state’s regulations if you plan to maintain an in-clinic pellet inventory.
Documentation Essentials for Every Hormone Pellet Insertion
- Pre-procedure labs (testosterone, estradiol, baseline values)
- Contraindication screening (documented as negative or addressed)
- Informed consent (signed and dated)
- Procedural note (pellet type, dose, lot number, insertion site)
- Post-procedure instructions (given to patient, copy in chart)
- Follow-up appointment scheduled (documented in EMR)
Clinics audited for compliance are evaluated on documentation completeness, not just clinical outcomes. Every hormone pellet insertion should have a complete audit trail from consultation through follow-up. Missing documentation is the most common compliance violation identified during payer audits or state board investigations.
Conclusion
The clinics that scale hormone pellet therapy without scaling overhead are the ones running it on a single platform – consent forms, lab tracking, lot-numbered procedural notes, modifier-correct claims, and 4-6 week follow-up reminders all firing automatically off one appointment. Doing it on disconnected tools is where extrusions get missed, J1073 units get under-billed, and follow-up labs slip past the dosing window.
Book a demo with Pabau to see how its HRT clinic software handles BHRT consent capture, pellet lot tracking, automated lab follow-ups, and CPT/HCPCS-aware billing inside a single patient record.
Continue your research
Need a structured workflow for patient consultations? How to Prepare for Cosmetic Client Consultations provides a step-by-step framework for consent, risk discussion, and expectation setting applicable to hormone therapy consultations.
Struggling with patient compliance for follow-up labs? Patient Compliance Guide covers automated reminders, educational messaging, and accountability frameworks that reduce no-show rates for post-procedure monitoring.
Looking to streamline clinical record-keeping? Client Record Management centralises patient histories, lab results, consent forms, and procedural notes in one searchable system, improving both efficiency and compliance.
Frequently Asked Questions
The procedure typically takes 10-15 minutes from site preparation through dressing application. Pre-procedure patient intake and post-procedure instructions add another 10-15 minutes to the total appointment time.
Most patients require pellet re-insertion every 3-6 months depending on their metabolism, activity level, and body weight. Follow-up labs at 4-6 weeks after insertion guide the timing of the next procedure.
Yes, both pellet types can be inserted in one appointment. Use separate insertion sites (one per hip) to minimise local inflammation and allow easier site monitoring. Bill each pellet type separately using the appropriate HCPCS codes.
Minor bruising at the insertion site is the most frequent complaint, occurring in 15-20% of patients. Serious complications (infection, pellet extrusion, hematoma) occur in less than 2% of cases when proper sterile technique is maintained.
Coverage varies significantly by payer. Medicare does not typically cover compounded pellets but may cover FDA-approved products like Testopel. Commercial insurers vary-some cover the procedure with prior authorization, others classify it as investigational. Verify benefits before the procedure to set accurate patient expectations.